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Abstract 
BACKGROUND: 
Asthma is a chronic respiratory disease, characterised by airways inflammation, obstruction and hyperresponsiveness. 
Asthma control is the goal of asthma treatment, but many patients have sub-optimal control. Exhaled NO and exhaled 
breath condensate (EBC) NO metabolites (nitrites and nitrates) measurements are non-invasive tools to assess airways 
inflammation. Our aim was to investigate the relationships between asthma control and the above-named biomarkers of 
airways inflammation. 
METHODS: 
Thirty-nine non-smoking asthmatic patients (19 women) aged 50 (21-80) years performed measurements of exhaled NO 
(FENO), EBC nitrates, nitrites and pH, and answered Asthma Control Questionnaire (ACQ) and Asthma Control Test 
(ACT)-questionnaire. 
RESULTS: 
The ACT and ACQ score were strongly interrelated (ρ = -0.84, p < 0.001). No relationships between ACT or ACQ 
score and FENO were found (p > 0.05). EBC nitrates were negatively related to ACT score (ρ = -0.34, p = 0.03) and 
positively related to ACQ score (ρ = 0.41, p = 0.001) while no relation of EBC nitrites to either ACQ or ACT score was 
found (p>0.05). 
CONCLUSION: 
EBC nitrates were the only biomarker that was significantly related to asthma control. This suggests that nitrates, but 
not nitrites or FENO, reflect an aspect of airways inflammation that is closer related to asthma symptoms. Therefore 
there is a potential role for EBC nitrates in objective assessment of asthma control. 
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Introduction 
Asthma is a chronic respiratory disease characterised by reversible airway obstruction, airway inflammation and 
hyperresponsiveness. Asthma control is sub-optimal in many patients despite available effective therapies1 and 
international guidelines for the diagnosis and management, based on clinical features and lung function tests.2 The 
recent update of international GINA guidelines2 suggests tailoring asthma treatment to the level of disease control rather 
than severity. Well-validated tools for assessing asthma control are available and two of the most widely used are 
Asthma Control Questionnaire (ACQ)3 and Asthma Control Test (ACT).4 These tools focus on the patient’s reported 
symptoms and additionally, lung function, in the case of ACQ. Neither symptoms nor lung function alone seems to 
adequately reflect the underlying level of airway inflammation. 
The analysis of exhaled breath is a non-invasive method to measure non-invasively airways inflammation in asthma and 
other respiratory diseases. Nitric oxide (NO) levels are increased in the air of asthmatic patients.5 Fraction of NO in the 
exhaled air (FENO) is considered an indirect marker of steroid-sensitive, eosinophilic airway inflammation and it has 
been used to tailor inhaled steroid therapy in asthma.6 However the level of evidence so far available could not 
recommend this approach for routine use.7 
Exhaled breath condensate is another easy-to-use technique and several markers in exhaled breath condensate (EBC) 
have been related to airways’ inflammation.8 In the airway surface liquid, NO reacts with oxygen forming nitrite and 
nitrate, stable-end products of NO,9 which can be measured in the EBC8 and might reflect NO formation in the airways. 
EBC pH can be measured reliably10 and the information regarding acidification of airways is regarded as relevant to 
asthma pathophysiology.11 
Increased levels of FENO and EBC nitrate, nitrite and sum of nitrite and nitrate (NOx) are reported in asthmatic 
subjects, when compared to healthy controls. 12 and 13 There are however fewer studies analysing the relation between 
these markers and asthma control. No relation between exhaled NO and asthma control is reported in cross-sectional 
studies.14, 15, 16 and 17 Peripheral airways inflammation, measured as increased alveolar NO, has been related to poor 
asthma control with contradictory results. 17, 18 and 19 The few studies that analysed the relation between nitrogen 
oxides in EBC and asthma control report contradictory results. 20, 21 and 22 No clear relationship has been established 
between EBC pH and asthma severity 23, 24 and 25 and no studies have reported a relationship between lower airways 
pH and poor asthma control. 
The main aim of this study was to investigate the relationships between EBC NO metabolites, nitrite and nitrate, EBC 
pH and asthma control. A secondary aim was to study the relationships between exhaled NO, and its estimated 
contributions from bronchial and alveolar compartment, and asthma control. 
Material and methods 
Study subjects 
Thirty-nine non-smoking consecutive patients (19 women) aged 21–80 years (median age 50 years) with previously 
diagnosed asthma were included in the study. All patients were coming for regular follow-up in the outpatient clinic of 
Dept. of Allergology of Mauriziano Hospital, Turin, Italy between November 2008 and July 2009. 
Exhaled NO measurements 
Exhaled NO was measured at 50, 100 and 200 mL/s with a chemiluminescence analyser (NIOX, Aerocrine AB, Solna, 
Sweden), according to current recommendations.26Estimation of alveolar and bronchial contributions to exhaled NO 
was done by the slope–intercept model27 using all the above mentioned flow-rates in 29 of the 39 subjects. Of those 
subjects, three had negative values of alveolar NO, leaving 26 subjects for further analyses. Alveolar NO was also 
calculated after adjustments for axial diffusion, according to Kerckx et al.28 
Exhaled breath condensate 
Exhaled breath condensate was collected with the R Tube EBC collection system (Respiratory Research, Inc, 
Charlottesville, Virginia, USA). EBC collections were obtained after thorough rinsing of mouth with water, at an initial 
condenser temperature of −20 °C, for 10 min. Samples were store at −80 °C until assays, which were performed within 
2 weeks of collection. 
The pH of EBC was assayed immediately potentiometrically with a glass microelectrode before and after bubbling 
200 μl of the sample with argon at 350 mL min−1 until pH reading was stable, as previously described.11 
A modified anion chromatographic technique for nitrate (NO2) and nitrite (NO3) determinations, described in a previous 
publication, was used for measurements of NO2and NO3 in EBC.29 Briefly, liquid chomatograph (Dionex, Sunnyvale, 
CA) equipped with a suppressed conductivity detector and an autosampling injector were used. The anion separator was 
an AG-4A-SC precolumn connected with an AS-4A column (Dionex). The eluent was an aqueous 1.28/1.60 mmol/L of 
sodium carbonate/bicarbonate solution flowing at 1.5 mL/min. Twenty-microlitre aliquots of EBC samples were 
injected into the column without pre-treatment. 
The intra-assay variability of the method (for NO2 and NO3 detection), assessed by using the coefficient of variation, is 
7 ± 1.2%.29 
ACQ 
ACQ3 is a tool to assess asthma control which consists of 7 items: 6 questions, 5 related to symptoms during the last 
week and one related to the use of short-acting beta2 agonists, and the seventh item is an objective measure – a 
spirometric assessment (FEV1% predicted). Each item has 7 alternatives of answer, scored from 0 to 6. The ACQ score 
is the mean of all these individual answers and therefore, it ranges also from 0 to 6 with higher scores standing for 
poorer control of asthma. A score of ≤0.75 has been associated with “well-controlled” asthma while a score ≥1.5 has 
been associated with “not well-controlled” asthma.30 
ACT 
Asthma control test is a questionnaire developed to assess asthma control.4 It consists of 5 questions, each with a 5 point 
scale from 1 (reporting all the time or very frequent the respective symptom) to 5 (never reporting the respective 
symptom). Therefore, the total ACT score is between 5 and 25, with a lower score standing for poorer controlled 
asthma. An ACT score ≥20 reflects well-controlled asthma.4 
Lung function 
Measurements of lung function were done with a water-sealed spirometer (Biomedin, Padua, Italy). The best of three 
measurements was automatically chosen by software. The parameters of interest were FEV1, FEV1/FVC-ratio, FEF25–
75%. 
Statistics 
Statistical analyses were performed using STATA 10 software (Stata Corp., Texas, USA). Values are presented as 
median (range) and non-parametric statistics methods (Spearman’s rank correlation test and Mann–Whitney U-test) 
have been used. 
A p-value of <0.05 was considered statistically significant. 
Ethics 
Informed and written consent was obtained from all participating patients and the protocol was approved by Local 
Ethics Committee. 
Results 
The characteristics of the 39 included asthmatic subjects are described in Table 1. 
 
Asthma control in the studied population 
The ACT score (median (range)) was 22 (8, 25) and the ACQ score (median (range)) was 0.71 (0, 3.86). The ACT and 
ACQ score were strongly related (ρ = −0.84, p < 0.001) (Fig. 1). The relation was similar in subjects with steroid doses 
<400 μg budesonide (ρ = −0.84, p < 0.001) (open circles) and steroid doses ≥400 μg budesonide (ρ = −0.84,p < 0.001) 
(closed diamonds). 
Asthma control and FENO 
FENO levels at the exhalation flow-rate of 50 mL/s were ranging from 14 to 173 ppb, with a median value of 35 ppb. 
No relation between ACQ or ACT score and FENO at any of the measured flow-rates and alveolar and bronchial 
contributions to exhaled NO was observed (all p-values > 0.05). No differences were observed when adjusting the 
alveolar NO for trumpet shape of the airways and axial diffusion. 
Asthma control and lung function 
Significant correlations were observed between asthma control and spirometric parameters recorded in the study (Table 
2). 
Asthma control and EBC markers 
EBC pH ranged between 6.55 and 7.33 with a median value of 7.07. No relation between ACQ score or ACT score and 
EBC pH was found (both p-values > 0.05). 
EBC NO3 ranged from 1.8 to 17 μM (median 6.5 μM) and EBC NO2 ranged from 0.06 to 3.11 μM (median 0.68 μM). 
EBC NO3 were negatively related to ACT score (ρ = −0.34,p = 0.03) and positively related to ACQ score 
(ρ = 0.41, p = 0.001) (Fig. 2A and B). No relation of EBC NO2 to either ACT score (p = 0.43) or ACQ score (p = 0.43) 
was found (Fig. 2C and D). Stratifying the subjects after the doses of inhaled steroids used, we could observe that the 
relationships between EBC NO3 and ACT or ACQ score were significant only in subjects on a dose of inhaled steroids 
of at least 400 μg budesonide (ρ = −0.56,p = 0.004 for ACT; and ρ = 0.58, p = 0.003 for ACQ). 
Using the sum of nitrite and nitrate, nitrogen oxides (NOx), significant relationships could be shown with the ACT score 
(ρ = −0.32, p = 0.05) and ACQ score (ρ = 0.36, p = 0.02). Similarly, this relation was found only in subjects on a dose 
of inhaled steroids of at least 400 μg budesonide (ρ = −0.46, p = 0.02 for ACT; and ρ = 0.46, p = 0.02 for ACQ score). 
The above reported results for nitrate were confirmed also when comparing the subjects with a good control of asthma 
vs those not controlled by means of ACT (p = 0.008) or ACQ (p = 0.03). This relation was stronger in subjects on doses 
of inhalation steroid ≥400 μg budesonide (p = 0.002 for ACT and p = 0.004 for ACQ score) (Fig. 3A and B). No 
differences in EBC nitrite were found between subjects with well-controlled vs not well-controlled asthma, either for all 
subjects or after stratifying the subjects according to the dose of inhaled budesonide (p > 0.30 for all) (see Fig. 3C and 
D for subjects on high doses of inhalation steroids). 
 
Effect of comorbidities and dose of inhaled steroids on asthma control, FENO and EBC markers 
Chronic rhinosinusitis was associated with higher ACQ scores (p = 0.05) and increased EBC NO3 levels (p = 0.04), 
with no effect on EBC pH, EBC NO2, FENO levels or ACT scores (all p-values > 0.2). 
Rhinitis was associated with higher ACQ scores (p = 0.008) and lower ACT scores (p = 0.03). No significant increase 
of EBC NO3 (p = 0.12) or significant associations with EBC NO2, EBC pH and FENO (all p-values > 0.2) and rhinitis 
were found. 
The dose of inhaled steroids was not significantly associated with ACQ and ACT scores, FENO, EBC NO3, EBC NO2, 
EBC pH (all p-values > 0.30). 
Discussion 
The main finding of the present study was that exhaled breath condensate nitrates concentration was related to asthma 
control, assessed by means of two of the most common used instruments, ACT and ACQ, either using absolute scores, 
or validated cut-offs for well-controlled asthma. On the other hand, no significant relationships were found between 
asthma control and EBC pH, EBC nitrites and exhaled NO, including its contributions from peripheral and central 
airways. 
The present study is one of the first studies looking separately at nitrates and nitrites in EBC when assessing their 
relation with asthma control. The NO metabolites in EBC have been previously reported to be increased in asthmatics 
compared to controls.12 and 13However few studies analysed separately nitrates,12 while most of the studies have used a 
combination of nitrates and nitrites.13 and 20 It is still a matter of debate which NO metabolite, measured in EBC, nitrites 
or nitrates, is better related to airways inflammation. Recently, both experimental31 and clinical studies,32 demonstrated 
that salivary nitrites concentration may influence EBC nitrites, but not nitrates concentration, suggesting that EBC 
nitrates, but not nitrites originate in the lower airways. That nitrates and not nitrites concentrations are a more reliable 
marker of inflammation is also suggested by previous observations that BAL nitrates and not nitrites concentrations 
were related to airways inflammation induced by segmental allergen challenge.33 Similarly, a recent study reported 
decrease of EBC nitrates, but not nitrites after treatment with a new anti-inflammatory drug.34 Moreover, increased EBC 
nitrates and decreased EBC nitrites concentrations have been found to be related to asthma severity in a Dutch study of 
asthmatic children.21 In our study no significant relationship between EBC nitrites and asthma control was found, in 
agreement with previous reports.20, 21 and 35 
EBC pH too was not related to asthma control in our patients. It is well known that exhaled breath condensate pH 
reflects acidification of airways and this process has been demonstrated to occur in acute asthma.11 In our study, we 
could not observe any differences in EBC pH between subjects with well-controlled and not well-controlled asthma, in 
agreement with a study in children, where EBC pH was not related neither to asthma severity nor to asthma 
control.21 Therefore the acidic stress of the airways is probably less important in stable asthma, compared to acute 
asthma. Moreover, the majority of our asthmatic patients had neutral–alkaline pH values, suggesting that no significant 
production of NO by nitrite reduction due to acidic environment took place in the airways of our asthmatic patients.11 
We did not find any significant relationship between exhaled NO and asthma control and this is in line with previous 
reports in adults and children,14, 15, 16 and 17 underlining that symptoms and airway inflammation are two separate 
aspects of asthma disease.36However in longitudinal studies,37 and 38 changes in FENO had been found to be related to 
changes in ACQ scores, both in smoking and non-smoking asthmatics. Alveolar NO has been reported in some small-
scale studies to be associated with more symptoms in both adults and children39 and 40 and two larger studies reported a 
significant association between poor asthma control and increased alveolar NO in children.18 and 19 However these 
results could not be confirmed in a recent large-scale pilot study which enrolled both children and adults,17 questioning 
the value of alveolar NO as a marker of asthma control, and our results agree with this study. 
Exhaled breath condensate nitrates and nitrites concentrations, EBC pH and exhaled nitric oxide were not significantly 
interrelated in our patients, as previously reported.20 and 32 This lack of correlations between exhaled NO and its 
metabolites and airway pH is probably explained by the complex biochemistry of nitrogen oxides in the airways, and 
more specifically in the airway surface liquid (ASL). While FENO mainly reflects the NO produced by epithelial 
iNOS,41 the nitrogen oxides reflect not only the oxidization of NO in the ASL, but they can also be generated through 
peroxidase-mediated reactions.42 This might be an explanation for divergent findings of normal NOx and low exhaled 
NO levels in cystic fibrosis patients. 43 Moreover a similar divergent pattern, with increased nitrate and decreased NO 
levels, has been observed immediately after allergen challenge.44 Our findings reinforce the current view that EBC 
nitrates are not an alternative to exhaled NO, but their measurement should be considered complementary to the exhaled 
NO measurements.45 
Almost all of our patients were receiving inhaled steroid therapy, which is well known to affect the levels of exhaled 
NO, leading to a prompt, dose-dependent decrease.46However, the effects of inhaled steroid treatment on EBC nitrites 
and nitrates are not so well studied. EBC NOx appear to decrease following inhaled steroid therapy, but this effect is 
smaller than the effect on FENO and it was not dose-dependent. 46 NOx are increased in the nasal lavage of patients with 
allergic rhinitis and these levels are not affected by intranasal steroids. 47 These observations might suggest that EBC 
NOx concentration is poorly affected by inhaled corticosteroids therapy, yielding another explanation for the lack of 
correlation between FENO and EBC nitrates and nitrites concentrations. We observed in our material that the relation 
between EBC nitrate and asthma control was driven by the group with more severe disease, requiring higher steroid 
doses. This observation is intriguing and suggests that similar FENO concentrations may not necessarily indicate the 
same level of airway inflammation, but instead may reflect decreased NO bioavailability from increased NO oxidation. 
Our asthmatics have a high prevalence of upper airway diseases, reflecting the interest of our clinic in this 
area.48 Chronic rhinosinusitis was associated with poorer asthma control in our patients, in agreement with the 
literature.49 No data exist on the levels of nitrates in EBC of patients with CRS, who have been reported to have lower 
levels of nitrate in nasal lavage.50 
In conclusion, EBC nitrates concentration was the only biomarker among those measured in the present study to be 
significantly related to asthma control. This suggests that EBC nitrates, but not EBC nitrites or FENO, reflect an aspect 
of airways inflammation that is closer related to asthma symptoms. These results reinforce the current view that 
nitrogen oxides measurements in EBC provide information on airway inflammation that is different from that obtained 
from exhaled NO measurements. Particularly, our results suggest a potential role for measuring EBC nitrates in order to 
obtain an objective marker of asthma control in asthmatic patients out of exacerbations. 
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        Table 1. Patients’ characteristics. 
 
Age (median (range)) 50 (21–80) 
Females (N (%)) 19 (49%) 
Atopy (N (%)) 30 (77%) 
Inhaled steroid therapy (N (%)) 
 No therapy 2 (5%) 
 <400 μga 15 
 400–800 μga 9 
 800–1200 μga 9 
 >1200 μga 4 (10%) 
Oral steroids (N (%)) 2 (5%) 
Rhinitis (N (%)) 32 (82%) 
Chronic rhinosinusitis (N (%)) 22 (56%) 
Nasal polyps (N (%)) 14 (36%) 
a Equivalent budesonide dose. 
 
Figure 1.  
Correlation between ACQ and ACT scores. Closed diamonds represent subjects on steroid doses <400 μg 
budesonide while open circles represent subjects on steroid doses ≥400 μg budesonide. 
 
 
 
 
Table 2. 
Relationships between asthma control (measured as either ACQ or ACT score) and lung function 
parameters. Results are presented as Spearman ρ (p-value). 
 
 ACQ score ACT score 
FEV1 (% pred) −0.61 (p < 0.001) 0.47 (p = 0.003) 
Tiffeneau index −0.42 (p = 0.008) 0.40 (p = 0.01) 
FEF25–75 (% pred) −0.49 (p = 0.001) 0.41 (p = 0.01) 
 
 
 
Figure 2.  
Correlation between EBC nitrate and ACT score (Panel A) and ACQ score (Panel B), respectively, as well as 
correlations between EBC nitrite and ACT score (Panel C) and ACQ score (Panel D). Closed diamonds represent 
subjects on steroid doses <400 μg budesonide while open circles represent subjects on steroid doses ≥400 μg 
budesonide. 
 
 
 
Figure 3.  
Box-plot of EBC nitrate (Panels A and B) and EBC nitrite (Panels C and D) in subjects on steroid doses ≥400 μg 
budesonide with well-controlled and not well-controlled asthma, according to ACT scores (Panels A and C) or ACQ 
scores (Panels B and D). Box-plot shows median (line), interquartile range (IQR) (box) and whiskers extend to 1.5 IQR. 
Values outside 1.5 IQR are considered outliers (dots). 
 
 
 
